Skincare Formulation Licensing Arbitration —  

1. Introduction

Skincare formulation licensing arbitration concerns disputes arising from agreements under which one party grants another party rights to use, manufacture, commercialize, distribute, or further develop a skincare formulation.

The licensed subject matter may include:

chemical formulations;

cosmetic compositions;

active ingredients;

proprietary blends;

manufacturing processes;

laboratory protocols;

stability data;

testing data;

clinical or dermatological data;

product specifications;

trademarks and trade dress;

patents and patent applications;

know-how and trade secrets;

regulatory dossiers; and

manufacturing procedures.

These agreements are particularly complex because a single skincare product may involve several layers of intellectual property. A company may own the trademark but license the formulation from a chemist, while a third-party manufacturer owns the manufacturing process and another company owns clinical or testing data.

Consequently, disputes frequently arise over:

ownership of the formulation;

scope of the licence;

exclusivity;

territorial rights;

royalty calculations;

minimum sales requirements;

formulation modifications;

manufacturing quality;

regulatory compliance;

confidentiality and trade secrets;

reverse engineering;

sublicensing;

termination;

post-termination use;

improvement technology; and

whether disputes involving patents, trademarks or regulatory rights are arbitrable.

There is unusually strong case law involving cosmetic and skincare licensing disputes, including the Bobo Labs, Neora/Nerium, and Kardashian/Hillair arbitrations. (Jus Mundi) 

2. What Is a Skincare Formulation Licence?

A typical formulation licence involves:

Licensor → formulation/know-how → Licensee → manufacture/market/sell skincare products

For example:

Company A develops an anti-aging cream containing a proprietary peptide formulation.

It licenses:

the formula;

manufacturing instructions;

laboratory specifications;

stability data; and

technical know-how

to Company B.

Company B agrees to pay:

upfront licence fees;

royalties;

milestone payments; and

minimum annual royalties.

An arbitration clause is inserted into the agreement.

A dispute may subsequently arise because Company B alleges that:

"The formulation supplied by A does not perform as promised."

A may respond:

"B modified the formulation without authorization."

The dispute can then proceed to arbitration.

3. Typical Disputes

A. Ownership of the formulation

The parties may disagree about whether the formulation belongs to:

the chemist;

the licensor;

the manufacturer;

the licensee; or

a jointly created entity.

This is particularly important where the licensee funds further research and development.

B. Scope of licence

The agreement may grant rights only for:

facial skincare;

but the licensee begins selling the formulation in:

body care;

hair care;

pharmaceutical products;

dermatological products.

The licensor may allege that the licensee exceeded the permitted field of use.

C. Exclusive versus non-exclusive licence

A dispute can arise when a licensor grants an "exclusive" licence but subsequently licenses the same formulation to another company.

The arbitrator may have to interpret:

exclusivity;

territory;

product category;

duration; and

reserved rights.

4. Case Law

Case 1 — Bobo Labs Inc. v. Benchmark Cosmetic Laboratories Inc. (C.D. Cal. 2023)

This is one of the closest authorities to formulation licensing arbitration.

Facts

Bobo Labs engaged Benchmark Cosmetic Laboratories in connection with developing skincare/cosmetic products.

The manufacturing and development agreement contained provisions concerning ownership of the formulation.

The agreement provided, in substance, that the formulation as a whole would belong to the client as a work made for hire after specified contractual conditions were satisfied. It also contained an assignment mechanism if the work-made-for-hire characterization was legally ineffective.

The dispute concerned rights in the formulation and related contractual obligations.

Bobo sought preliminary injunctive relief in court, while Benchmark moved to compel arbitration.

Decision

The U.S. District Court for the Central District of California granted the motion to compel arbitration and stayed the litigation pending arbitration. (Jus Mundi) 

Importance

This case demonstrates a central principle of skincare formulation arbitration:

Ownership of a formulation and contractual rights concerning that formulation can be determined within an arbitration framework where the agreement contains a valid arbitration clause.

Lessons

A formulation agreement should expressly address:

who owns the initial formula;

who owns improvements;

who owns manufacturing procedures;

when ownership transfers;

whether payment is a condition of ownership;

whether the licensee can modify the formula;

whether the licensor retains residual rights.

5. Case 2 — Neora, LLC v. Nerium Biotechnology, Inc. & Nerium Skincare, Inc.

Background

This is an especially important skincare intellectual-property arbitration.

The parties were involved in the skincare industry and entered into a settlement agreement and an Omnibus Intellectual Property Assignment and License Agreement.

The agreements concerned intellectual-property rights connected with the skincare business.

The agreement contained an arbitration provision providing for AAA arbitration in Dallas.

The arbitration involved claims and counterclaims relating to:

breach of agreement;

intellectual-property rights;

trademarks;

domain names;

copyrightable materials; and

other contractual obligations. (Jus Mundi) 

Arbitration

The arbitrator issued a final award on June 7, 2021.

Nerium Biotechnology and Nerium Skincare subsequently sought to have portions of the award vacated.

The Texas trial court rejected the challenge and confirmed the award.

Appellate decision

In Nerium Biotechnology, Inc. & Nerium Skincare, Inc. v. Neora, LLC, the Texas Fifth District Court of Appeals affirmed.

The appellants argued that:

the arbitrator exceeded the scope of the arbitration agreement; and

the damages determination was legally unsupported.

The appellate court rejected those arguments. (Justia Law) 

Principle

An arbitration agreement expressly making arbitration the exclusive remedy for disputes arising under or relating to an IP agreement can give an arbitrator substantial authority over contractual and IP-related disputes.

Relevance to skincare formulation licensing

This is highly relevant where a formulation licence also covers:

trademarks;

product names;

patents;

know-how;

domain names;

marketing materials;

copyright;

confidential information.

A carefully drafted arbitration clause can therefore consolidate these disputes rather than forcing the parties into multiple proceedings.

6. Case 3 — KimsAPrincess, Inc. v. Hillair Capital Management, LLC / Hillair Capital Investments v. West — Kardashian Cosmetic Licensing Arbitration

This is another major authority.

Background

The Kardashian parties entered into a licensing agreement with Boldface Licensing + Branding concerning the development, manufacture, distribution, advertising and sale of specified cosmetic products.

The agreement involved:

trademarks;

images;

likenesses;

cosmetic products;

marketing;

production appearances; and

royalty payments.

Haven Beauty later acquired rights associated with the cosmetic business.

Disputes arose concerning the licensing relationship and royalty obligations.

Arbitration

The Kardashians initiated arbitration under the licensing agreement.

The arbitration resulted in an award exceeding $11 million, including amounts relating to royalty and indemnification obligations. The trial court confirmed the award. (CounselStack Law) 

Appellate decision

The California Court of Appeal affirmed the judgment.

The dispute demonstrates that an arbitration clause within a beauty/cosmetics licensing agreement can encompass major disputes involving:

royalties;

contractual performance;

licensing rights;

marketing obligations;

indemnity;

intellectual property;

termination.

The arbitration was not treated as a peripheral issue; it was the principal dispute-resolution mechanism. (CounselStack Law) 

Principle

A comprehensive cosmetics licensing agreement can place the economic and intellectual-property consequences of the entire commercial relationship before an arbitral tribunal.

Importance for skincare formulation agreements

If a skincare formulation licence combines:

formula + trademark + marketing + royalties + manufacturing,

one comprehensive arbitration clause can potentially cover all these interconnected disputes.

7. Case 4 — KimsAPrincess, Inc. v. Hillair Capital Management, LLC, Final Arbitration Award (2019)

The arbitration itself is sufficiently significant to be treated separately from the subsequent court proceedings.

The arbitral panel expressly exercised jurisdiction under the parties' licensing agreement and considered claims involving the cosmetic licensing relationship.

The underlying agreement gave Boldface rights to use the Kardashians' marks, images and likenesses for the development, manufacture, distribution, promotion and sale of cosmetic products. (Jus Mundi) 

The award demonstrates that an arbitrator may address the commercial substance of a cosmetics licensing relationship, including:

royalty obligations;

licensing performance;

contractual breaches;

indemnification;

intellectual-property rights; and

related counterclaims.

Principle

Where the arbitration agreement is broad, the tribunal may determine not merely whether a licence existed but also the financial consequences of breaches of the licence.

8. Case 5 — Matter of Sivanesan v. YBF, LLC, 2024 N.Y. Slip Op. 04327

This case involves a cosmetic trademark licensing business and arbitration.

Facts

YBF, LLC operated a business involving retail cosmetic products marketed under the YBF marks.

YBF had previously granted an exclusive licence concerning those marks.

A consulting agreement was subsequently entered into under which the consultant would receive:

hourly consulting fees; and

a transaction fee tied to the equity of the entity operating the beauty business and holding rights to exploit the marks.

The agreement contained a binding JAMS arbitration provision.

A dispute arose concerning whether the consultant had earned the transaction fee associated with the licensing transaction. (New York Courts) 

Arbitration

The arbitration therefore concerned the economic consequences of a transaction involving cosmetic trademark licensing rights.

Principle

The case demonstrates that disputes surrounding the creation, transfer or recovery of cosmetic licensing rights may extend beyond straightforward royalty disputes and include:

transaction fees;

consulting obligations;

recovery of licensing rights;

ownership/control of beauty businesses.

Relevance

In a skincare formulation licence, similar questions may arise where a consultant or technology developer is entitled to:

milestone payments;

equity;

transaction fees;

royalties; or

success fees.

9. Case 6 — American Laser Skincare, LLC v. Morgan, N.D. Ill. 2013

Although this case concerned a skincare business rather than a formulation licence itself, it is valuable for the relationship between skincare commercial agreements and arbitration.

Facts

American Laser Skincare sued a former consultant over alleged breaches of:

noncompetition obligations;

nonsolicitation obligations; and

payment obligations.

The defendant had already filed an arbitration demand with the AAA and sought to compel arbitration.

The court examined the parties' consulting agreement and the arbitration framework. (Justia Law) 

Principle

A commercial agreement involving a skincare enterprise may send disputes concerning:

restrictive covenants;

payments;

consultancy obligations; and

contractual performance

to arbitration when the agreement so provides.

Relevance

Formulation licensing agreements often include:

non-compete provisions;

non-solicitation;

confidentiality;

non-use;

non-disclosure;

post-termination restrictions.

American Laser Skincare illustrates why those related contractual obligations should be expressly addressed in the arbitration clause.

10. Case 7 — Thomas v. Cook & Ardyss International Inc., Texas Court of Appeals (2011)

Facts

The dispute concerned an Ardyss distribution agreement involving products including:

cosmetics;

underwear; and

weight-loss supplements.

The contract incorporated an arbitration provision from the company's policies and procedures manual.

A dispute subsequently arose regarding compensation and the parties' contractual relationship.

The trial court confirmed an arbitration award, and the Texas Court of Appeals affirmed. (Justia Law) 

Principle

An arbitration clause incorporated through contractual documents can be enforceable when the underlying agreement sufficiently incorporates the relevant policies.

Relevance to formulation licensing

Skincare companies frequently have separate:

quality-control manuals;

manufacturing specifications;

technical protocols;

product standards;

compliance manuals.

The Thomas principle illustrates why the licence should clearly state which incorporated technical documents form part of the arbitration agreement.

11. Case 8 — Vargison v. Paula's Choice LLC, W.D. Wash. 2025

This is a modern skincare arbitration case, although it concerns consumer terms rather than formulation licensing.

Facts

Paula's Choice manufactures and sells skincare products.

Consumers alleged that the company misrepresented its products as:

cruelty-free; and

never tested on animals.

The company sought to compel certain plaintiffs to arbitration under an arbitration clause in its Terms of Use. (Justia Law) 

Importance

The case illustrates the increasing use of arbitration provisions in the online skincare industry.

For formulation licensing, the lesson is broader:

The scope and enforceability of the arbitration agreement must be separately analyzed from the merits of the underlying skincare dispute.

12. Case 9 — Ramirez v. Trusper, Inc. d/b/a Musely, N.D. Cal. 2024

Musely is a skincare company providing telehealth-based treatment for skin conditions.

The company attempted to compel arbitration under its online participation agreement.

The plaintiff alleged privacy violations relating to the collection and transmission of health information.

The court denied the motion to compel arbitration, examining whether the plaintiff had actually agreed to the arbitration provision through the online enrollment process. (Justia Law) 

Principle

Even a broad arbitration clause is ineffective if the party seeking arbitration cannot establish valid contractual assent.

Relevance

This is important for modern skincare licensing relationships involving:

online portals;

electronic acceptance;

digital formulation databases;

cloud-based laboratory systems;

electronic technical documentation.

13. Case 10 — Santic v. Coty DTC Holdings LLC, W.D. Wash. 2026

This recent case involves Kylie Cosmetics, a Coty business.

The company's Terms contained a broad arbitration clause covering claims relating to goods and services, including contract, tort and statutory claims, while excluding certain intellectual-property injunction claims from mandatory arbitration.

The court denied the motion to compel arbitration in the particular dispute. (Justia Law) 

Importance

This illustrates an important drafting lesson:

A licensing agreement should expressly state which IP remedies remain available in court and which disputes must go to arbitration.

This becomes particularly important when the licensee is accused of unauthorized use of:

a formulation;

trademark;

trade secret;

patent;

product design.

14. Most Important Case-Law Principles

15. Ownership of the Formula

This is usually the most commercially important issue.

A formulation agreement should distinguish among:

Background IP

Technology existing before the agreement.

Example:

Licensor's original retinol formulation.

Foreground IP

Technology created during the relationship.

Example:

New cream formulation jointly developed by the licensor and licensee.

Improvements

Changes to the original formula.

Example:

Licensee develops a more stable version of the original formulation.

Manufacturing know-how

The method by which the formula is produced.

Example:

Temperature, mixing sequence and processing time.

Failure to distinguish these categories creates major arbitration disputes.

16. Formulation Ownership and Bobo Labs

The Bobo Labs dispute illustrates precisely why this issue should be drafted carefully.

The agreement contemplated ownership of the formulation and manufacturing procedures and addressed circumstances in which the work-made-for-hire characterization might not legally operate.

The existence of such detailed contractual allocation demonstrates that formulation ownership should never be left to implication. (Jus Mundi) 

17. Royalty Disputes

Royalty clauses may be based on:

Gross sales

Example:

5% of gross sales.

Net sales

Example:

7% of net sales after specified deductions.

Per-unit royalty

Example:

₹20 per unit sold.

Milestone royalty

Example:

₹50 lakh upon regulatory approval.

Minimum royalty

Example:

Licensee must pay ₹1 crore annually regardless of actual sales.

Disputes frequently concern:

returns;

discounts;

free samples;

bundled products;

promotional sales;

related-party sales;

online marketplace sales;

foreign currency conversion;

taxes.

The Kardashian/Hillair arbitration illustrates how substantial royalty obligations can become a central part of a cosmetics licensing arbitration. (CounselStack Law) 

18. Quality-Control Disputes

Skincare formulation licences normally impose quality requirements.

The licensee may be required to comply with:

formulation specifications;

ingredient concentrations;

microbial limits;

stability requirements;

packaging requirements;

manufacturing standards;

testing requirements;

regulatory standards.

A licensor may allege:

"The licensee changed the concentration of the active ingredient."

The licensee may respond:

"The modification was necessary to comply with local regulations."

This can become an arbitration dispute concerning both contract interpretation and regulatory compliance.

19. Regulatory Compliance

A skincare formulation cannot be treated solely as intellectual property.

It may also be subject to:

cosmetics legislation;

manufacturing requirements;

ingredient restrictions;

labeling requirements;

safety assessments;

product registration;

advertising restrictions;

import/export requirements.

In India, the Cosmetics Rules, 2020 and the Drugs and Cosmetics Act, 1940 can become relevant depending on the product and transaction.

A formulation licence should therefore state:

Which party bears responsibility for regulatory approval?

Possible allocation:

Licensor

provides technical dossier;

provides formulation;

provides safety information.

Licensee

obtains local registration;

manufactures;

labels;

distributes.

20. Trade Secrets

Many skincare formulations may be protected more effectively as trade secrets/confidential know-how than through patents.

Confidential information may include:

exact percentages;

mixing sequence;

heating/cooling procedures;

ingredient suppliers;

stability data;

testing protocols;

manufacturing parameters.

An arbitration clause should therefore be accompanied by:

confidentiality obligations;

restricted disclosure;

document-protection procedures;

protective orders;

expert confidentiality;

limits on public disclosure of the award.

21. Patent Disputes

Suppose the formulation is patented.

A dispute may involve:

"Licensee has exceeded the patent licence."

The parties should distinguish:

Contractual dispute

Example:

Whether the licensee breached the licence agreement.

Patent validity

Example:

Whether the patent itself is invalid.

Patent infringement

Example:

Whether a third party infringed the patent.

These issues can have different arbitrability consequences depending on the applicable jurisdiction.

The arbitration clause should therefore clearly identify the contractual IP disputes intended to be arbitrated.

22. Trademark and Formulation Rights

A skincare licence often combines:

Trademark + formulation + packaging + marketing rights.

For example:

Brand owner owns the trademark, while the laboratory owns the formulation.

The licensee receives both rights.

A termination dispute may therefore raise:

Can the brand continue to be used?

Can the formula continue to be manufactured?

Can existing inventory be sold?

Can the licensee use the formula under a different trademark?

Can the licensor transfer the formula to another manufacturer?

The arbitration clause should cover these questions expressly.

23. Modification of the Formula

This is an especially important drafting issue.

Suppose the licensed formulation contains:

2% active ingredient A.

The licensee changes it to:

1.5% active ingredient A + 0.5% active ingredient B.

Who owns the modified formula?

Possible contractual approaches are:

Approach 1 — Licensor ownership

All improvements automatically belong to the licensor.

Approach 2 — Licensee ownership

Licensee owns improvements it independently creates.

Approach 3 — Joint ownership

Both parties own the improvements.

Approach 4 — Cross-licensing

Each party retains ownership but grants the other continuing rights.

This should be expressly defined because arbitrators may otherwise have to reconstruct the parties' intentions from technical documents and correspondence.

24. Reverse Engineering

A licensee may attempt to analyze the formulation to:

improve it;

manufacture a substitute;

create a competing product.

The agreement should specify whether reverse engineering is:

completely prohibited;

permitted for quality control;

permitted for regulatory purposes;

permitted for improvement;

permitted after termination.

This can become both a trade-secret dispute and a contractual arbitration dispute.

25. Termination

Termination is one of the most common arbitration issues.

Possible grounds include:

failure to pay royalties;

failure to meet minimum sales;

unauthorized sublicensing;

quality failures;

regulatory violations;

misuse of confidential information;

change of control;

insolvency;

reputational harm.

After termination, the critical question becomes:

Can the licensee continue using the formulation?

The agreement should specify:

sell-off period;

destruction of stock;

return of technical documents;

cessation of manufacture;

deletion of electronic copies;

termination of sublicences;

continued confidentiality.

26. Interim Relief

Formulation disputes often require urgent relief.

For example:

Licensee is allegedly preparing to disclose a confidential formulation to a competitor.

Waiting two years for a final arbitration award could make the remedy meaningless.

The agreement should therefore permit:

emergency arbitration;

interim injunctions;

confidentiality orders;

preservation of evidence;

temporary restrictions on manufacturing or disclosure.

The parties should also specify whether courts retain jurisdiction for emergency IP protection.

27. Indian Legal Framework

For an Indian skincare formulation licensing agreement, the principal statutory framework would generally include:

Arbitration and Conciliation Act, 1996

Particularly:

Section 7 — arbitration agreement;

Section 8 — reference to arbitration;

Section 9 — interim measures by courts;

Section 11 — appointment of arbitrators;

Section 16 — kompetenz-kompetenz;

Section 17 — interim measures by tribunal;

Section 34 — setting aside awards;

Section 36 — enforcement of awards.

Contract Act, 1872

Important for:

formation;

consideration;

breach;

damages;

indemnity;

interpretation.

Trade Marks Act, 1999

Relevant where the licence includes:

brand;

logo;

packaging;

trade dress.

Patents Act, 1970

Relevant where the formulation or manufacturing technology is patented.

Copyright Act, 1957

Potentially relevant to:

formulation documentation;

technical manuals;

artwork;

packaging;

promotional content.

Consumer and cosmetics regulation

Depending upon the transaction, the applicable consumer and cosmetics regulatory framework must also be considered.

28. Indian Case Law on Arbitrability

Booz Allen & Hamilton Inc. v. SBI Home Finance Ltd., (2011) 5 SCC 532

The Supreme Court distinguished disputes involving rights in rem from disputes involving rights in personam.

For formulation licensing, ordinary contractual disputes concerning:

royalties;

payments;

confidentiality;

manufacturing obligations;

contractual licence scope

are generally conceptually different from disputes concerning statutory rights that cannot legally be determined privately.

A. Ayyasamy v. A. Paramasivam, (2016) 10 SCC 386

The Supreme Court considered fraud and arbitration.

For skincare licensing, a fraud allegation such as:

"The licensor falsely represented the effectiveness of the formulation"

does not automatically mean the entire dispute becomes non-arbitrable.

The exact nature of the fraud and relief sought matters.

Vidya Drolia v. Durga Trading Corporation, (2021) 2 SCC 1

This is particularly important for formulation licensing.

The Supreme Court developed the modern framework for identifying non-arbitrable disputes.

The central lesson is:

Not every statutory or IP-related dispute is automatically outside arbitration, but disputes involving rights or remedies reserved exclusively to public adjudication may be non-arbitrable.

29. Confidentiality in Arbitration

Formulation arbitration can involve commercially catastrophic disclosures.

Imagine the arbitral record contains:

"Formula consists of 0.8% ingredient A, 1.2% ingredient B, 0.4% peptide C..."

Public disclosure could destroy the commercial value of the formulation.

Therefore, the arbitration agreement should provide for:

confidential hearings;

confidential pleadings;

sealed technical exhibits;

restricted expert access;

confidentiality undertakings;

redacted awards where necessary.

30. Expert Evidence

Formulation disputes frequently require experts.

Possible experts include:

cosmetic chemists;

pharmaceutical scientists;

dermatologists;

toxicologists;

regulatory consultants;

manufacturing specialists;

accountants.

The tribunal may need to determine whether a disputed product is:

chemically equivalent;

substantially similar;

materially modified;

stable;

safe;

compliant with specifications.

31. Damages

An arbitrator may have to calculate:

Lost royalties

If the licensee underreported sales.

Lost profits

If unauthorized termination caused commercial loss.

Unjust enrichment

If the licensee continued using the formulation after termination.

Development costs

If the licensor failed to deliver usable technical materials.

Cost of reformulation

If the supplied formulation was defective.

Brand damage

Where legally recoverable.

32. Important Drafting Problem: "Formulation" Must Be Defined

A good agreement should define Formulation broadly enough to include:

recipes, compositions, ingredient percentages, specifications, manufacturing processes, laboratory methods, stability information, technical data, improvements, modifications and related know-how.

Otherwise, a dispute may arise over whether:

"the manufacturing procedure"

is included in:

"the licensed formulation."

The Bobo Labs dispute demonstrates why precise allocation of formulation and manufacturing rights is commercially important. (Jus Mundi) 

33. Model Arbitration Clause

A comprehensive clause could provide:

Arbitration. Any dispute, controversy or claim arising out of or relating to this Agreement, the Licensed Formulation, formulation specifications, manufacturing processes, improvements, intellectual property, royalties, payments, quality requirements, regulatory responsibilities, confidentiality, sublicensing, modification, termination or post-termination use of the Licensed Formulation shall be finally resolved by binding arbitration. The tribunal shall have jurisdiction over contractual claims and all other claims legally capable of being determined by arbitration. The arbitration shall be conducted by three arbitrators where the amount in dispute exceeds the agreed threshold and by a sole arbitrator in all other cases. The proceedings, technical evidence and award shall remain confidential except to the extent disclosure is required by law or necessary to enforce the award. Nothing in this clause prevents either party from seeking urgent interim relief from a competent court or emergency arbitrator to protect confidential information, trade secrets or intellectual-property rights.

34. Recommended Contract Structure

A sophisticated skincare formulation licence should contain separate clauses for:

Definitions

Grant of licence

Territory

Field of use

Exclusivity

Formulation ownership

Background IP

Improvements

Manufacturing know-how

Regulatory approvals

Quality control

Testing

Confidentiality

Trade secrets

Royalty

Audit rights

Minimum sales

Sublicensing

Change of control

Termination

Post-termination rights

Inventory sell-off

Dispute resolution

Emergency relief

Governing law

Seat of arbitration

Confidentiality of arbitration

35. Key Lessons from the Case Law

1. Formulation ownership should never be left ambiguous

Bobo Labs demonstrates the importance of contractual allocation of formulation ownership. (Jus Mundi) 

2. Broad IP arbitration clauses can be powerful

Neora/Nerium demonstrates that an arbitration clause can cover a wide range of contractual and IP disputes arising from a skincare relationship. (Justia Law) 

3. Cosmetic licensing disputes can generate enormous royalty claims

The Kardashian/Hillair arbitration illustrates the financial importance of royalty and licensing obligations. (CounselStack Law) 

4. Licensing transactions can generate ancillary fee disputes

Sivanesan v. YBF demonstrates how consulting and transaction-fee claims can become connected to cosmetic licensing rights. (New York Courts) 

5. Valid assent remains essential

Ramirez v. Trusper/Musely shows that a skincare business cannot rely on an arbitration clause unless it establishes contractual assent. (Justia Law) 

6. Incorporated documents must be carefully drafted

Thomas v. Cook/Ardyss demonstrates the importance of properly incorporating arbitration provisions contained in policies or manuals. (Justia Law) 

7. IP remedies should be expressly addressed

The Santic v. Coty litigation illustrates why agreements should distinguish arbitrable contractual claims from judicial IP remedies where necessary. (Justia Law) 

36. Conclusion

Skincare formulation licensing arbitration sits at the intersection of contract law, intellectual-property law, cosmetics regulation, trade-secret protection and commercial arbitration.

The most important disputes generally concern:

who owns the formula;

who owns improvements;

what exactly has been licensed;

where and for which products it may be used;

how royalties are calculated;

whether the licensee complied with quality requirements;

whether the formulation can be modified;

whether confidential know-how was misused;

whether the licence survived termination; and

which IP disputes can actually be determined by an arbitrator.

The strongest directly relevant authorities include Bobo Labs v. Benchmark, Neora v. Nerium Biotechnology/Nerium Skincare, the KimsAPrincess/Hillair cosmetics licensing arbitration, and Sivanesan v. YBF. They demonstrate that arbitration is particularly suitable for complex commercial disputes involving formulations, cosmetic products, licensing rights, royalties and related intellectual property. (Jus Mundi) 

For an Indian skincare formulation licence, the safest approach is to draft the arbitration provision together with detailed provisions on formulation ownership, improvements, trade secrets, regulatory responsibility, royalties, audit rights, post-termination use and emergency IP relief, while preserving matters that Indian law treats as non-arbitrable.